4.2 Article

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma

Related references

Note: Only part of the references are listed.
Review Clinical Neurology

The 2007 WHO classification of tumours of the central nervous system

David N. Louis et al.

ACTA NEUROPATHOLOGICA (2007)

Article Clinical Neurology

Is protracted low-dose temozolomide feasible in glioma patients?

A Tosoni et al.

NEUROLOGY (2006)

Letter Oncology

How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience

W Wick et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Article Medicine, General & Internal

MGMT gene silencing and benefit from temozolomide in glioblastoma

ME Hegi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Medicine, General & Internal

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

M Esteller et al.

NEW ENGLAND JOURNAL OF MEDICINE (2000)